72 related articles for article (PubMed ID: 10837621)
41. T-cell activation or tolerization: the Yin and Yang of bacterial superantigens.
Sähr A; Förmer S; Hildebrand D; Heeg K
Front Microbiol; 2015; 6():1153. PubMed ID: 26539181
[TBL] [Abstract][Full Text] [Related]
42. 'Man-Made' Malaria in India.
Sinton JA
Ind Med Gaz; 1936 Apr; 71(4):181-187. PubMed ID: 29013029
[No Abstract] [Full Text] [Related]
43. Man in the Sea.
Spilhaus AF
Science; 1964 Sep; 145(3636):993. PubMed ID: 17802183
[No Abstract] [Full Text] [Related]
44. Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival.
Knopick P; Terman D; Riha N; Alvine T; Larson R; Badiou C; Lina G; Ballantyne J; Bradley D
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33109631
[TBL] [Abstract][Full Text] [Related]
45. Design of split superantigen fusion proteins for cancer immunotherapy.
Golob-Urbanc A; Rajčević U; Strmšek Ž; Jerala R
J Biol Chem; 2019 Apr; 294(16):6294-6305. PubMed ID: 30782846
[TBL] [Abstract][Full Text] [Related]
46. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.
Thibodeau J; Bourgeois-Daigneault MC; Lapointe R
Oncoimmunology; 2012 Sep; 1(6):908-916. PubMed ID: 23162758
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.
Shaw DM; Connolly NB; Patel PM; Kilany S; Hedlund G; Nordle O; Forsberg G; Zweit J; Stern PL; Hawkins RE
Br J Cancer; 2007 Feb; 96(4):567-74. PubMed ID: 17285137
[TBL] [Abstract][Full Text] [Related]
48. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
49. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
50. Man-made superantigens: Tumor-selective agents for T-cell-based therapy.
Dohlsten M; Kalland T; Gunnarsson P; Antonsson P; Molander A; Olsson J; d'Argy R; Ohlsson L; Soegaard M; Persson R; Brodin TN
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):131-142. PubMed ID: 10837621
[TBL] [Abstract][Full Text] [Related]
51. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2.
Fernández MM; Bhattacharya S; De Marzi MC; Brown PH; Kerzic M; Schuck P; Mariuzza RA; Malchiodi EL
Proteins; 2007 Jul; 68(1):389-402. PubMed ID: 17427250
[TBL] [Abstract][Full Text] [Related]
52. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes.
Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN
J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729
[TBL] [Abstract][Full Text] [Related]
53. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
54. Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen.
Diaz LA; Pai R; Endres J; Anthony P; Duzyj C; Bishu S; Morita Y; Fox DA
J Lab Clin Med; 2003 Sep; 142(3):149-57. PubMed ID: 14532902
[TBL] [Abstract][Full Text] [Related]
55. Interplay between superantigens and immunoreceptors.
Petersson K; Forsberg G; Walse B
Scand J Immunol; 2004 Apr; 59(4):345-55. PubMed ID: 15049778
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
